Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium

SummaryRecent studies have noted specific expression of hepatocyte nuclear factor (HNF) 1β in ovarian clear-cell adenocarcinoma (CCA). In this study, we aimed to determine whether HNF-1β can be a specific marker of CCA in both the ovary and the endometrium and to assess the pathological significance of HNF-1β expression in CCAs. We examined HNF-1β expression immunohistochemically in 186 ovarian carcinomas, including 40 CCAs; 33 endometrial carcinomas, including 5 CCAs; 22 endometria at different stages of the menstrual cycle (5 in the proliferative, 12 in the secretory, and 5 in the menstrual phases); and 7 gestational endometria. The incidence of HNF-1β immunoreactivity differed significantly between CCAs and other histology in both the ovary (100% in the former versus 2% in the latter) and the endometrium (100% in the former versus 0% in the latter) (P < .0001 each). In nonneoplastic endometrium, 25% or more immunoreactive cells were confined to the mid-to-late secretory phase of the menstrual cycle and gestational endometrium. HNF-1β would be an excellent marker for distinguishing CCAs from other lesions in both the ovary and the endometrium. HNF-1β expression seems to be associated with physiopathological cytoplasmic glycogen accumulation in these organs.